| 書目名稱 | Resistance of Cancer Cells to CTL-Mediated Immunotherapy |
| 編輯 | Benjamin Bonavida,Salem Chouaib |
| 視頻video | http://file.papertrans.cn/829/828446/828446.mp4 |
| 概述 | Explores the inhibition of CTL-cytotoxic function by tumor-derived T-regulatory cells, along with the inhibition of cytotoxic function by tumor induction of hypoxia.Discusses the overexpression of tra |
| 叢書名稱 | Resistance to Targeted Anti-Cancer Therapeutics |
| 圖書封面 |  |
| 描述 | This comprehensive volume explores the latest research on the?mechanisms of resistance in cancer cells to CTL-mediated immunotherapy.?Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for?CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more. |
| 出版日期 | Book 2015 |
| 關(guān)鍵詞 | HDAC inhibitors; Proteasome inhibitors; apoptosis; cytotoxic t lymphocytes; drug-resistant cancer cells; |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-319-17807-3 |
| isbn_softcover | 978-3-319-38067-4 |
| isbn_ebook | 978-3-319-17807-3Series ISSN 2196-5501 Series E-ISSN 2196-551X |
| issn_series | 2196-5501 |
| copyright | Springer International Publishing Switzerland 2015 |